- Randomized, double-blind, double-dummy phase 3 study comparing once daily oral rivaroxaban (a new oral factor Xa inhibitor) with adjusted-dose oral warfarin for the prevention of stroke in subjects with non-valvular AF - Population and treatment: 14 000 high-risk patients with AF Randomized to 20-mg rivaroxaban once daily (or 15 mg in patients with moderate renal impairment at screening) or to dose-adjusted warfarin (titrated to an INR of 2.5) - Primary outcome: A composite of stroke and non-CNS embolism See the article at http://www.theheart.org/article/1148785.do

4. ROCKET AF: Commentary* *All comments from Off orbit? ROCKET AF: Rivaroxaban noninferior to warfarin, but superiority analyses at odds (http://www.theheart.org/article/1148785.do) "I think it's totally fair to say that the trial did not demonstrate superiority by the high standard, according to the usual rules of clinical trials." - Dr Robert Califf (co–principal investigator) "If you take away only the conclusion of noninferiority, that's a step up; warfarin is a very difficult drug to use." - Dr Douglas Zipes "This was an impressive trial because the patients were so sick." - Dr Gordon Tomaselli